Quartz 4

mitotane_pharmacology_and_monitoring_in_acc

52 min read

Mitotane Pharmacology and Monitoring in ACC

Systemic Therapy Backbone

Mitotane pharmacology and monitoring in adrenocortical carcinoma (ACC) concerns the use of the only approved adrenal-directed systemic drug for this malignancy, with emphasis on its unusual disposition, narrow therapeutic window, endocrine effects, and extensive interaction profile.123 Within ACC care, mitotane is used both as adjuvant therapy in selected high-risk postoperative settings and as a systemic backbone for advanced disease, either alone in carefully selected patients or in combination regimens such as EDP-mitotane.453

Mitotane differs from most anticancer drugs because it is highly lipophilic, accumulates in adipose and other tissues, reaches clinically relevant circulating concentrations slowly, and may persist for months after dose reduction or discontinuation.678 As a result, prescribed dose correlates imperfectly with exposure, and therapeutic drug monitoring has become standard practice, usually aiming for plasma trough concentrations of approximately 14 to 20 mg/L as a pragmatic balance between antitumor activity and toxicity.91011

The evidence supporting this approach remains limited by the rarity of ACC. Most data derive from retrospective cohorts, pharmacokinetic modeling, mechanistic studies, and case reports rather than randomized trials of exposure-guided dosing or monitoring strategies.12113 Higher mitotane exposure has repeatedly been associated with better tumor response or survival, but these associations may be influenced by treatment duration, survivorship bias, disease burden, and patient selection.141516 Mitotane monitoring is therefore best understood as a widely adopted clinical tool supported by consistent observational signals rather than definitive prospective validation.

Its pharmacology is also inseparable from its toxicity. Adrenal insufficiency, gastrointestinal intolerance, neurotoxicity, dyslipidemia, and drug-drug interactions are common enough that monitoring extends beyond drug levels to include steroid replacement, metabolic surveillance, and repeated medication review.17181920 This broader monitoring framework is reliable in practice, even though the precise relationship between total plasma levels and individual toxicity remains imperfect.2122

Therapeutic context in ACC

Mitotane occupies a distinct position within ACC management. Surgery remains the only potentially curative treatment, whereas mitotane is primarily used to reduce recurrence risk after resection in selected patients, to help control hormone excess, and to treat unresectable or metastatic disease.425 In advanced disease, it generally complements rather than replaces more rapid cytoreductive approaches such as combination chemotherapy or selected local therapies.2324

This distinction is clinically important because mitotane often acts slowly. Retrospective and review data suggest that mitotane monotherapy may be most relevant in lower-volume, more indolent, or hormonally active disease, whereas patients with rapidly progressive or high-burden metastatic ACC usually require combination treatment, most commonly EDP-mitotane.252627 That comparative principle is reasonably consistent across the literature, although direct randomized evidence for many sequencing decisions is lacking.45

Pharmacologic basis

Mechanistically, mitotane appears to exert both adrenolytic and steroidogenesis-inhibiting effects. Experimental studies support selective adrenal injury involving mitochondrial dysfunction, altered membrane behavior, oxidative stress, and suppression of steroidogenic pathways rather than simple nonspecific cytotoxicity.28293031 Earlier metabolic studies also suggest that bioactivation within adrenal tissue may contribute to activity, which may partly explain heterogeneous tumor sensitivity.323334

These mechanistic observations are biologically coherent, but they are not yet clinically predictive. No routine biomarker or functional assay reliably identifies which ACCs will respond to mitotane, so treatment selection still relies mainly on clinical setting rather than pharmacologic precision.353

Pharmacokinetics and therapeutic drug monitoring

Exposure variability

Marked interpatient pharmacokinetic variability is one of the central features of mitotane therapy. Poor aqueous solubility, variable oral absorption, extensive lipoprotein binding, very large distribution volume, and prolonged elimination all contribute to delayed and unpredictable achievement of target concentrations.367837 Body composition, serum lipid fractions, autoinduction, sex-related differences, and pharmacogenetic variation may all influence exposure.3839404142

This variability is well established and explains why fixed-dose prescribing alone is unreliable. In practice, serial plasma monitoring is usually required during initiation and dose adjustment because both underexposure and toxicity may occur despite apparently conventional dosing.431013

Therapeutic range

Observational studies broadly support a therapeutic window centered on trough levels of about 14 to 20 mg/L. Concentrations below this range have often been associated with lower response rates or shorter disease control, whereas concentrations above 20 mg/L are associated with more frequent serious neurologic toxicity.4491445 More recent work suggests that early exposure and cumulative time spent within range may be more informative than any single measurement.1516

The therapeutic window is clinically useful but not absolute. Exceptional responses have been reported at lower measured concentrations, and translational work suggests that total plasma concentration may not fully represent biologically active drug in every patient.464748 The practical implication is that mitotane levels should inform, but not replace, clinical assessment of radiographic behavior, endocrine control, adherence, and toxicity.

Sampling and assay pitfalls

Because mitotane accumulates and washes out slowly, monitoring is generally performed during treatment initiation, dose escalation, toxicity evaluation, interruption, and sometimes after discontinuation when clinically relevant exposure may persist.495010 Early-morning trough sampling is preferred because post-dose measurements may rise substantially and can mislead dose adjustment.51

Interpretation of measured levels has important technical limitations. Hypercholesterolemia, hypertriglyceridemia, and postprandial lipemia may artifactually increase reported concentrations and create discordance between laboratory values and the clinical picture.215222 This pitfall is sufficiently well described that fasting sampling, concurrent lipid review, and lipid-aware laboratory methods are clinically relevant when unexpectedly high levels are reported without corresponding toxicity.

Clinical activity and treatment patterns

The delayed onset of effective exposure shapes how mitotane is used. Therapeutic concentrations often require weeks to months to achieve, and objective responses to monotherapy are uncommon but not absent.95326 Retrospective series suggest that durable benefit is more likely in selected patients with lower tumor burden or slower-growing disease, while most patients with aggressive metastatic ACC require combination treatment for earlier disease control.252624

This also complicates response assessment. Limited evidence suggests that early radiographic progression does not always represent definitive treatment failure, particularly when deterioration is modest and mitotane exposure remains subtherapeutic.5455 However, prolonged continuation without biochemical, radiographic, or symptomatic benefit remains uncertain, and long-survivor analyses suggest that most meaningful responses emerge within the first year.56 The reliable conclusion is that delayed benefit may occur, but prolonged ineffective treatment should not be justified by pharmacologic optimism alone.

Endocrine, metabolic, and neurologic consequences

Mitotane commonly causes adrenal insufficiency through both direct adrenal toxicity and accelerated steroid metabolism, making glucocorticoid replacement a routine component of care and often at higher doses than in other forms of adrenal failure.57172 Mineralocorticoid replacement may also be required, and endocrine effects can persist after treatment cessation because washout is prolonged.583 This relationship is clinically reliable; underreplacement may mimic drug intolerance, fatigue, or disease progression.

Metabolic effects, especially dyslipidemia, are frequent and may become clinically significant early in treatment.1819 Estrogen-like and reproductive effects have also been described, with preclinical support for estrogen receptor activation as one possible mechanism.59 These effects justify routine lipid surveillance and symptom-directed endocrine follow-up, although individual susceptibility remains difficult to predict.

Neurologic and gastrointestinal toxicities are the principal dose-limiting adverse effects. Nausea, vomiting, diarrhea, anorexia, fatigue, cognitive change, ataxia, and encephalopathic presentations become more likely at higher concentrations and may improve only gradually because tissue elimination is prolonged.60616220 In practice, new neurologic symptoms warrant prompt review of mitotane levels and dose reassessment, especially when concentrations approach or exceed the upper therapeutic boundary.962

Drug interactions and ongoing research

Mitotane is a major perpetrator of drug-drug interactions, largely through induction of CYP3A4 and related pathways.506364 This may reduce exposure to glucocorticoids, supportive medications, and some anticancer agents, including etoposide, and the effect may persist long after discontinuation.501765 The interaction burden is among the most actionable aspects of mitotane pharmacology, making medication review essential rather than optional.

Current research mainly aims to reduce pharmacologic unpredictability rather than replace monitoring. Major directions include population pharmacokinetic modeling, pharmacogenetic predictors of underexposure, improved oral formulations, and refinement of how total, free, and lipoprotein-bound mitotane should be interpreted.7401366 These approaches remain investigational, and none has yet supplanted conventional plasma-level monitoring in routine ACC care.163

Included Articles

  • PMID 1137262: This early case report describes two patients with invasive or metastatic adrenocortical carcinoma who had prolonged recurrence-free survival after extensive tumor excision followed by immediate postoperative o,p’DDD therapy with steroid replacement. The report contrasts these exceptional outcomes with prior series showing much shorter average response duration and survival.67
  • PMID 2380344: A 1990 pilot study evaluated suramin as single-agent therapy in metastatic or unresectable adrenocortical carcinoma, showing limited but measurable activity with partial responses, minor responses, and temporary stable disease. The report also found in vitro cytotoxicity against ACC cell lines and suppression of steroid production at clinically achievable concentrations.68
  • PMID 2388676: This letter discusses mitotane treatment in ACC, noting low objective response in one series, uncertain survival benefit overall, and the possibility that serum mitotane exposure influences outcomes. It highlights formulation-dependent absorption, delayed attainment of steady-state levels over 6 to 8 weeks, and the unresolved value of therapeutic drug monitoring.69
  • PMID 2949824: This case series describes advanced hormone-producing ACC treated with continuous mitotane plus intermittent streptozocin, with two initially inoperable primary tumors becoming resectable after prolonged therapy and one patient achieving long-term disease-free follow-up. A third postoperative metastatic case did not respond, underscoring variable activity and toxicity.70
  • PMID 3510844: This review describes surgery as primary therapy for adrenocortical carcinoma and presents mitotane as the only available drug at the time associated with extended survival, while emphasizing its substantial gastrointestinal and neurologic toxicity. It also notes that aminoglutethimide can provide rapid antihormonal symptom control in functioning tumors without antitumor activity.71
  • PMID 3874792: This experimental study examined mitotane (o,p’-DDD), a drug used to treat adrenocortical carcinoma, and found in vitro inhibition of adrenal steroidogenic enzymes including 3β-HSD, 11β-hydroxylase, and 18-hydroxylase, with partial reversal by NAD or NADPH. It also reported inhibition of hepatic 5β-reductase–mediated cortisol metabolism at high concentrations.72
  • PMID 5034421: This early case series describes mitotane treatment in 19 patients with inoperable ACC, noting frequent steroid suppression and occasional regression of measurable pulmonary metastases, while large abdominal or retroperitoneal masses did not clearly regress. Treatment commonly caused adrenal insufficiency requiring glucocorticoid and sometimes mineralocorticoid replacement.57
  • PMID 5819718: This case report describes metastatic ACC treated with oral O,P’-DDD at up to 8 g daily, producing objective regression of liver, lung, spine, and abdominal metastases for 237 days. Treatment was accompanied by rapid declines in urinary and plasma steroid markers and was fairly well tolerated aside from nausea, vomiting, hypercholesterolemia, and decreased PBI.73
  • PMID 6097439: This case report describes an inoperable steroid-secreting ACC whose primary tumor decreased in CT-measured volume during o,p’-DDD therapy, regrew rapidly after drug withdrawal, and again diminished after treatment resumed. The report also notes endocrine suppression and neuropsychiatric toxicity requiring hydrocortisone support and symptom management.74
  • PMID 6537915: In metastatic or spilled adrenocortical carcinoma treated with o,p’-DDD, objective regression and longer survival were mainly observed when serum drug levels exceeded about 14 µg/ml for sustained periods, while levels below 10 µg/ml showed little apparent benefit. Serum levels above 20 µg/ml were associated with reversible neuromuscular toxicity, supporting routine therapeutic drug monitoring.44
  • PMID 6715193: In a rat adrenocortical carcinoma model, o,p’-DDD treatment reduced tumor weight and increased necrosis, with electron microscopy showing marked mitochondrial deformation and cristae destruction but intact nuclei. The findings support a cytotoxic mitochondrial mechanism rather than a purely cytostatic effect.28
  • PMID 7172409: In metastatic adrenocortical carcinoma treated with mitotane, plasma concentrations correlated with adipose, tumor, and brain tissue levels, supporting plasma monitoring as a practical surrogate for tissue exposure. The study also notes a narrow therapeutic range, with prior observations of limited tumor regression below 10 µg/ml and neurological toxicity above 20 µg/ml.75
  • PMID 7340988: This pharmacokinetic study of mitotane in patients with adrenocortical carcinoma found that fat-containing vehicles such as milk, chocolate, and oil emulsion produced higher plasma levels than tablets, while granules performed worst. During maintenance therapy, regular plasma monitoring was recommended because drug elimination after long-term treatment was highly prolonged and variable.6
  • PMID 7738789: This preclinical pharmacology study examined mitotane metabolism and covalent binding in adrenal cortex homogenates and a human adrenocortical carcinoma cell line. Findings support formation of an acyl chloride intermediate from mitotane that generates the DDA metabolite and binds mainly to adrenal cortical proteins, informing understanding of mitotane’s adrenocorticolytic mechanism.32
  • PMID 7763292: This preclinical pharmacology study found that bovine adrenal cortex metabolizes mitotane predominantly to the acetic acid derivative DDA, with o,p’-DDD showing greater DDA formation, covalent tissue binding, and suppression of H-295 cell growth and cortisol production than m,p’- or p,p’-isomers. The authors propose that adrenal beta-carbon hydroxylation contributes to adrenalytic activity, whereas alpha-carbon hydroxylation may represent deactivation.33
  • PMID 8005209: This case report describes metastatic androgen-producing ACC with unresectable multifocal liver metastases achieving radiographic complete remission for nearly four years on mitotane after prior surgery, radiotherapy, and metastasectomies. Gastrointestinal toxicity was dose dependent and improved with dose reduction alongside steroid replacement.76
  • PMID 8180029: In a consecutive series of 96 patients with adrenocortical carcinoma, mitotane was associated with improved survival only when maintenance serum trough concentrations reached 14 mg/L or higher. Low serum levels appeared no better than no mitotane, while complete tumor resection remained strongly associated with longer survival.77
  • PMID 8418229: In a phase II multicenter trial for metastatic or residual unresectable adrenocortical carcinoma, cisplatin plus mitotane produced an objective response rate of 30%, median response duration of 7.9 months, and median overall survival of 11.8 months, with frequent moderate to severe gastrointestinal, renal, and neurologic toxicity.78
  • PMID 8585118: This article describes a practical plasma HPLC assay for mitotane and its metabolite with good linearity, recovery, and reproducibility, supporting therapeutic drug monitoring during ACC treatment. The report emphasizes mitotane’s narrow therapeutic window, slow elimination, and the need for dose adjustment to balance efficacy and toxicity.49
  • PMID 10730906: This case report describes recurrent metastatic ACC with complete radiographic remission for about 2 years on mitotane despite delayed initiation after surgery and serum drug levels remaining below 10 µg/ml. It also documents later clinical resistance with rapid progression and more mitotically active tumor at autopsy.46
  • PMID 10852456: In a prospective series of eight ACC patients, low-dose mitotane with plasma-level monitoring reached the proposed therapeutic range of 14-20 µg/mL in all patients after 3-5 months, with generally manageable toxicity. The report supports dose tailoring and steroid replacement to improve tolerability compared with traditional high-dose regimens.43
  • PMID 11494911: In a small clinical series of metastatic or recurrent ACC treated with o,p’-DDD (mitotane/Lysodren), outcomes and toxicity appeared strongly linked to serum drug levels. Patients reaching levels above 14 µg/ml had longer survival, while levels above 20 µg/ml were associated with intolerable adverse effects, supporting therapeutic drug monitoring and individualized dosing.79
  • PMID 11508789: This case report describes two women with recurrent or metastatic adrenocortical carcinoma who achieved prolonged radiographic and clinical disease control during continuous long-term mitotane, including maintenance at low doses of 1 g/day after initial higher dosing. Treatment was generally tolerated, but required management of adrenal insufficiency, hypercholesterolemia, and in one patient premature menopause.80
  • PMID 11745214: A prospective single-center study found that plasma mitotane levels above 14 mg/L were associated with objective responses in metastatic ACC, while levels above 20 mg/L correlated with grade 3 to 4 neurologic toxicity. Reaching target trough levels often required several months, and daily dose explained only part of plasma level variability.9
  • PMID 11889204: An ex vivo human adrenal tissue study found selective binding of mitotane and MeSO2-DDE to zona fasciculata/reticularis and to cells from an aldosterone-producing ACC metastasis. Metyrapone nearly abolished MeSO2-DDE binding but only partly reduced mitotane binding, suggesting different CYP11B1 dependence and highlighting mechanistic limits of current adrenocorticolytic therapy.81
  • PMID 14042612: This early case series describes o,p’-DDD as an adrenocorticolytic systemic therapy for functioning adrenocortical carcinoma, reporting decreased urinary steroid excretion and objective regression or disappearance of metastases in some patients. It also highlights important limitations including gastrointestinal and neuropsychiatric toxicity, adrenal insufficiency, nondefinitive responses, and acquired resistance.82
  • PMID 14280300: This case report describes metastatic hormone-secreting pediatric ACC treated with oral o,p’-DDD after postoperative progression in the lungs and liver. At about 8 g daily, the drug was associated with biochemical improvement, adrenal suppression requiring cortisone, and radiographic regression of metastases, but residual viable tumor remained and survival was short.83
  • PMID 16402938: This preliminary study reports that an accelerated high-dose mitotane schedule using pure o,p’DDD tablets reached the therapeutic plasma threshold above 14 µg/ml within 2 to 4 weeks in ACC patients treated at least 1 month, with reversible digestive and neurologic toxicity requiring close biweekly drug-level and clinical monitoring.84
  • PMID 18525324: In a retrospective single-center cohort of 57 adults with predominantly stage IV ACC treated with first-line systemic therapy, no conventional regimen showed a clear overall survival advantage. Time to progression differed across groups, with mitotane alone showing the longest median time to progression in this dataset, underscoring the limited efficacy of historical frontline options.85
  • PMID 18764725: This review summarizes systemic treatment for advanced or unresectable ACC, emphasizing limited efficacy of mitotane and cytotoxic chemotherapy. Mitotane showed partial responses in a minority of patients, requires serum level monitoring because of a narrow therapeutic index, and combination chemotherapy regimens produced only modest overall response rates.86
  • PMID 19574489: This case report describes metastatic virilizing ACC achieving a durable complete response after radical nephroadrenalectomy followed by 5 months of oral mitotane. The review emphasizes mitotane dose titration and plasma level monitoring, noting optimal responses around 14 to 20 mg/L, frequent toxicities, and the need for steroid replacement.87
  • PMID 19778161: This preclinical formulation study addresses mitotane delivery, reporting that a self-microemulsifying oral formulation increased intestinal permeation and achieved 3.4-fold higher relative bioavailability in rabbits than conventional Lysodren. The work highlights mitotane’s poor oral solubility and the need for high doses and prolonged time to reach therapeutic plasma levels.36
  • PMID 20044879: In H295R human adrenocortical cells, mitotane enantiomers showed small but statistically significant differences in cytotoxicity and suppression of cortisol and DHEA secretion. The authors conclude these direct cellular differences do not justify single-enantiomer use alone, though stereochemical pharmacokinetic effects in vivo could still matter.88
  • PMID 20105188: This comparative assay study supports therapeutic drug monitoring of mitotane in ACC, noting prior evidence that serum levels above 14 mg/l are associated with tumor response and improved survival. Two different serum assays showed strong agreement, suggesting monitoring results are clinically comparable across methods.89
  • PMID 21029628: In a retrospective series of 12 stage IV ACC cases, multimodality treatment centered on resection of the primary tumor followed by systemic chemotherapy, with selective transarterial chemotherapy or radiotherapy, produced partial responses in 7 patients, median progression-free survival of 9 months, and median overall survival of 14 months.90
  • PMID 21212436: This review summarizes the limited standard systemic options for advanced ACC, emphasizing mitotane as the longstanding adrenolytic backbone with modest and unpredictable response rates, substantial toxicity, and the need for serum-level monitoring. It also notes historically disappointing cytotoxic chemotherapy results and the trial effort to define more effective first- and second-line regimens.12
  • PMID 21220434: In patients with ACC, mitotane showed a strong and long-lasting induction of CYP3A4 activity, markedly lowering exposure to midazolam and sunitinib, including months after mitotane discontinuation. These findings support careful attention to drug-drug interactions and therapeutic monitoring during mitotane-based treatment.50
  • PMID 21470991: In advanced ACC treated with mitotane, achieving plasma o,p’DDD concentrations of at least 14 mg/liter was associated with higher objective response rates and longer survival in this retrospective multicenter study. Higher mitotane levels and combined measurement of o,p’DDD with o,p’DDA improved specificity for predicting tumor response.14
  • PMID 21854357: This review outlines the historical medical-treatment backbone for advanced ACC, emphasizing mitotane as the only approved adrenal-specific drug, the importance of serum level monitoring with a suggested therapeutic threshold above 14 mg/L, and the role of combination chemotherapy such as EDP-mitotane versus streptozotocin-mitotane.91
  • PMID 21883349: This review highlights that mitotane strongly induces CYP3A4, reducing exposure to many concomitant drugs and potentially some antitumor agents used in ACC. It emphasizes increased glucocorticoid replacement needs during mitotane therapy, persistence of interactions after discontinuation, and the need to choose alternative co-medications carefully.17
  • PMID 22008276: This 2011 therapeutic review summarizes that complete resection remains the only curative option, while unresectable or metastatic ACC is conventionally treated with mitotane-based systemic therapy. It highlights FIRM-ACT results supporting EDP plus mitotane over streptozotocin plus mitotane, and notes the mitotane therapeutic window of 14 to 20 mg/L.4
  • PMID 22048971: A prospective single-center study evaluated high-dose mitotane initiation with monthly plasma monitoring during the first 3 months. High-dose dosing produced therapeutic plasma levels above 14 mg/l in 27% by 1 month and 45% within 3 months, with grade 3-4 neurologic or hematologic toxicity in 13.6%, supporting early level-guided dose adjustment based on tolerance.53
  • PMID 22161625: This review summarizes 2011 management of advanced ACC, emphasizing mitotane as the only approved systemic drug, the need for plasma level monitoring, and its delayed antisecretory and antiproliferative effects. It also notes that no polychemotherapy regimen had proven superior, so less toxic regimens and selective locoregional therapies should be considered.92
  • PMID 22259022: This case-based analytical study supports mitotane therapeutic monitoring in ACC by describing a validated SPE-HPLC assay for mitotane and its main metabolites in plasma, red cells, and urine. It also reiterates a therapeutic plasma range of 14-20 µg/mL with acceptable toxicity and highlights interpatient variability in mitotane metabolism.93
  • PMID 22382612: This review frames mitotane as the main ACC-specific systemic therapy for advanced disease and an increasingly used adjuvant option after complete resection, while emphasizing substantial uncertainty from retrospective, nonstandardized evidence. It also outlines key pharmacologic features including adrenolytic and steroidogenesis-inhibiting effects, lipophilic tissue distribution, and prolonged half-life.1
  • PMID 22934112: This review describes mitotane as the principal medical therapy for inoperable or advanced ACC, emphasizing its adrenolytic mechanism, narrow therapeutic window, need for plasma level monitoring, glucocorticoid replacement, and substantial toxicity. It also identifies EDP plus mitotane and streptozotocin plus mitotane as the leading combination regimens under study for unresectable stage III-IV disease.94
  • PMID 22934807: This review emphasizes mitotane as the cornerstone systemic therapy for advanced or metastatic ACC, while noting its limited bioavailability, narrow therapeutic window, need for high cumulative dosing, and frequent toxicities. It also highlights investigational strategies such as lipid nanocarriers and S-(-)-mitotane enrichment to improve delivery and efficacy.95
  • PMID 23013780: In a small retrospective ACC series, mitotane treatment was not associated with clinically relevant QTc prolongation or documented torsades de pointes, including in some patients with plasma levels above the usual therapeutic window. The study supports cardiovascular electrical safety as a limited but reassuring aspect of mitotane tolerability.96
  • PMID 23179081: This mechanistic study shows that mitotane activates the steroid and xenobiotic receptor, inducing CYP3A4 expression and activity in human hepatocyte-derived cells. The findings support clinically relevant drug-drug interactions and help explain increased glucocorticoid clearance and altered metabolism of coadministered agents during mitotane therapy.63
  • PMID 23696597: This preclinical study examines mitotane’s cellular mechanism in human adrenocortical cell lines, showing that clinically relevant concentrations impair proliferation, suppress cortisol and 17-hydroxyprogesterone secretion, and induce a selective mitochondrial respiratory chain complex IV defect with altered steroidogenic gene expression.29
  • PMID 23814013: This in vitro study reports that mitotane directly reduces viability and ACTH secretion in mouse and human ACTH-secreting pituitary adenoma cells, with effects appearing at concentrations within the ACC therapeutic window. The article also reiterates that ACC tumor response is associated with mitotane blood levels of at least 14 mg/l and a therapeutic range of 14-20 mg/l.97
  • PMID 24057287: In advanced ACC, a prospective multicenter trial found that high-dose versus low-dose mitotane initiation did not significantly improve 12-week plasma levels or adverse-event rates overall. Concomitant chemotherapy affected exposure, supporting high-dose initiation mainly for mitotane monotherapy and a lower starting dose when combined therapy is used.98
  • PMID 24348556: In a retrospective ACC cohort, mitotane therapy was associated with significant increases in HDL cholesterol, LDL cholesterol, and triglycerides. HDL rise correlated with serum mitotane concentration, whereas LDL and triglyceride increases did not, highlighting a clinically relevant metabolic toxicity profile during mitotane treatment.18
  • PMID 24887633: This study developed and externally validated a three-compartment pharmacokinetic model for mitotane, showing slow clearance, very large distribution volume, and delayed attainment of the therapeutic plasma target above 14 mg/L. The model supports individualized dose adjustment using serial plasma levels to reduce underdosing and early toxicity.7
  • PMID 24958272: This review summarizes metastatic ACC treatment around mitotane and cytotoxic chemotherapy, noting modest overall activity and few durable responses. It highlights mitotane therapeutic drug monitoring with a target plasma range of 14–20 mg/L, endocrine replacement needs, and FIRM-ACT evidence supporting EDP-mitotane over streptozotocin-mitotane for progression control.23
  • PMID 25026941: This preclinical study examined mitotane and its metabolite o,p’DDA in ACC models and found that o,p’DDA lacked antiproliferative and mitochondrial effects seen with mitotane. The findings support mitotane itself, rather than o,p’DDA, as the agent driving adrenal cellular dysfunction, while highlighting persistent uncertainty about mitotane mechanism of action.35
  • PMID 25144285: This case report describes widely metastatic, nonfunctioning ACC with a dramatic and prolonged response to mitotane monotherapy, followed by local treatment of a residual liver lesion and resection of an isolated pulmonary recurrence. The discussion also summarizes that mitotane alone may be considered for low-volume metastatic disease, whereas mitotane plus EDP is favored for higher tumor burden.99
  • PMID 25201518: In ACC patients on maintenance mitotane who had previously reached therapeutic concentrations, plasma levels varied substantially over the day, with a median 24% rise 4 hours after a morning dose. The study supports standardized early-morning trough sampling to guide mitotane monitoring and avoid inappropriate dose adjustments.51
  • PMID 25542188: This in vitro study shows that mitotane and its metabolite o,p’-DDE can strongly induce multiple drug-metabolizing enzymes and transporters, including CYP3A4, via PXR activation, while also potently inhibiting CYP2C19. The findings highlight mitotane as a major source of pharmacokinetic drug-drug interactions relevant to combination ACC therapy and therapeutic drug monitoring.64
  • PMID 26120791: This study suggests mitotane efficacy in ACC depends partly on its lipoprotein-free fraction rather than total plasma exposure alone. Lipoprotein-free mitotane showed greater cellular uptake, mitochondrial accumulation, antiproliferative and pro-apoptotic activity, and concurrent statin use was retrospectively associated with higher tumor control.47
  • PMID 26242497: A case report highlights that mitotane can reach toxic plasma concentrations despite relatively low daily dosing, causing symptoms such as asthenia, nausea, and vomiting. It supports therapeutic drug monitoring with plasma targets around 14-20 mg/L and dose adjustment to limit toxicity while maintaining treatment exposure.100
  • PMID 26444320: A case report describes mitotane-associated drug-induced subacute cutaneous lupus erythematosus in a woman treated after resection of nonfunctioning stage II ACC. The papulosquamous eruption appeared about 1 month after starting mitotane and resolved completely within 3 weeks of discontinuation.101
  • PMID 26671975: This case-based translational study shows that most circulating mitotane is bound to serum lipoproteins and that chylomicron-associated absorption likely contributes to its pharmacokinetics. Lipoprotein binding reduced mitotane’s in vitro antiproliferative and antihormonal activity, supporting practical relevance for therapeutic drug monitoring and interpretation of serum levels.102
  • PMID 26961793: In heavily pretreated advanced ACC progressing after mitotane and a median of three prior systemic regimens, salvage trofosfamide showed generally good tolerability but limited antitumor activity, with stable disease in 3 of 21 evaluable patients, median progression-free survival of 84 days, and median overall survival of 198 days.103
  • PMID 27002491: This mechanistic study examines mitotane, the only approved drug for adrenocortical carcinoma, showing that it inserts into the lipid-water interface of membranes and disrupts bilayer structure and permeability in a lipid composition-dependent manner. The inactive metabolite o,p’-DDA binds membranes but does not produce the same disruptive effects.30
  • PMID 27043680: This case report describes an exceptional adult metastatic ACC response to mitotane monotherapy, with therapeutic plasma levels reached within 2 months, FDG-PET complete metabolic remission by 4 months, CT remission by 7 months, and durable disease-free survival for 10 years on maintenance treatment.104
  • PMID 27063476: This multicenter retrospective ACC study found that therapeutic mitotane plasma levels of 14-20 mg/L were reached at least once in 70% of patients after a median of 4 months, and sustained for more than 2 months in 61% of evaluable cases. ENSAT stage remained the main prognostic factor, while sustained therapeutic mitotane levels were independently associated with better overall survival despite frequent nonserious toxicity and high discontinuation rates.15
  • PMID 27298727: In mitotane-treated ACC, hypercholesterolemia and hypertriglyceridemia can artifactually elevate plasma mitotane and o,p′-DDE measurements through an analytical matrix effect, potentially disconnecting measured levels from toxicity. Routine lipid monitoring and corrective laboratory methods such as plasma dilution or phospholipid removal may improve interpretation of high mitotane concentrations.21
  • PMID 27887670: This case report suggests that early radiographic progression during mitotane plus platinum-etoposide does not necessarily indicate treatment failure in metastatic ACC. A delayed partial response emerged months after therapeutic mitotane plasma levels were reached and persisted long term with continued mitotane and locoregional treatment.54
  • PMID 28079787: This case report describes a previously unreported mucosal toxicity of mitotane in ACC: biopsy-supported oral and vulvo-vaginal erosive lichenoid reactions arising about six months after treatment initiation. The lesions were refractory to several standard therapies, creating a difficult benefit-risk decision because mitotane was considered not readily replaceable.105
  • PMID 28184938: This review summarizes the historical systemic treatment backbone for advanced ACC, highlighting mitotane as the only approved drug, the need for therapeutic drug monitoring with target plasma levels, and the FIRM-ACT evidence favoring etoposide-doxorubicin-cisplatin plus mitotane over streptozotocin plus mitotane for response outcomes without overall survival improvement.27
  • PMID 28432798: This article emphasizes therapeutic drug monitoring as a practical component of mitotane treatment in ACC, supporting a target plasma trough range of 14-20 mg/L to balance efficacy and toxicity. It also notes the long half-life, delayed steady state, and recommended frequent monitoring during initiation, dose adjustment, and after interruption.10
  • PMID 28456766: This review summarizes mitotane as the principal adrenolytic drug used for postoperative, recurrent, and inoperable ACC, while emphasizing that its survival benefit remains uncertain in some settings. It highlights preclinical evidence that mitotane preferentially injures adrenal cortical cells through mitochondrial dysfunction, oxidative stress, apoptosis, and suppression of steroidogenesis.31
  • PMID 28559412: In a retrospective series of 36 patients with metastatic ACC treated with single-agent mitotane, most had rapid progression and substantial toxicity, but 8% achieved complete responses. Responders had nonfunctional, limited-volume disease, while adrenal insufficiency and other severe toxicities were common and often required dose interruption or reduction.25
  • PMID 28809444: In postoperative ACC patients receiving adjuvant mitotane, plasma mitotane and metabolite levels showed circannual variation, and male patients required significantly higher mitotane doses than female patients to reach the therapeutic window. The study supports ongoing therapeutic drug monitoring and notes the need for larger confirmatory cohorts.106
  • PMID 28983351: This case-based review describes metastatic ACC treatment with EDP-mitotane, including mitotane target blood levels of 14-20 mg/L and glucocorticoid replacement, and summarizes evidence that EDP-mitotane improves response rate and progression-free survival versus streptozotocin-mitotane without a clear overall survival advantage.107
  • PMID 29071575: In metastatic ACC long-term survivors treated with standard systemic therapy, most partial responses occurred within 6 months of starting mitotane or polychemotherapy with or without mitotane, and nearly all occurred within 1 year. The study suggests that lack of response beyond this window may indicate treatment failure, particularly for prolonged mitotane continuation.56
  • PMID 29192018: This case report highlights severe mitotane neurotoxicity in ACC, describing high-dose treatment associated with encephalopathy at a plasma concentration of 47.8 mg/L after prolonged exposure. It emphasizes narrow therapeutic-range monitoring, recognition of early neurologic symptoms, and prompt consideration of discontinuation given mitotane’s long terminal half-life.60
  • PMID 29452402: In advanced ACC treated with mitotane monotherapy, objective response occurred in 20.5% and median progression-free and overall survival were 4.1 and 18.5 months. Better outcomes were associated with lower tumor burden, delayed advanced recurrence, and achieving mitotane blood levels above 14 mg/L.26
  • PMID 29650402: This case report highlights mitotane-induced severe hypercholesterolemia as a treatment-limiting toxicity in ACC, including CYP3A4-mediated statin interaction considerations and the importance of maintaining therapeutic mitotane plasma levels. PCSK9 inhibition with evolocumab produced partial LDL lowering and facilitated mitotane dose escalation in one patient.108
  • PMID 30087117: This study models mitotane pharmacokinetics in ACC, supporting time-dependent enzyme autoinduction, very large distribution volume, and marked interindividual variability. Simulations suggest high-dose initiation may achieve therapeutic concentrations faster, with therapeutic drug monitoring around day 16 to help avoid toxicity.38
  • PMID 30173131: This case report describes dyspnoea as a previously unreported possible adverse effect of mitotane in ACC, with symptom worsening after dose escalation and improvement after dose reduction or discontinuation despite therapeutic drug levels. It also reinforces the need for pharmacokinetic-guided dosing and careful toxicity monitoring during mitotane therapy.109
  • PMID 30349596: This review summarizes mitotane as the core approved medical therapy for ACC, emphasizing its therapeutic plasma window of 14–20 mg/L, the need for regular level monitoring, and its limited but established role in advanced disease and selected postoperative settings. It also outlines toxicity, drug interactions, and replacement needs caused by treatment-induced adrenal insufficiency.2
  • PMID 30533000: In metastatic ACC, this pilot study found that concomitant mitotane markedly increased etoposide clearance and lowered exposure, potentially reducing the efficacy of platinum-etoposide therapy. The authors suggest that etoposide dose escalation with close toxicity monitoring may help overcome this pharmacokinetic interaction.65
  • PMID 30831058: This case report describes therapeutic drug monitoring–guided mitotane dose optimization in metastatic ACC, showing that severe neurologic and gastrointestinal toxicity at standard dosing corresponded to supratherapeutic plasma levels and that long-term disease control was maintained after large dose reduction with trough-level monitoring.110
  • PMID 31093700: Mitotane requires therapeutic drug monitoring because clinical benefit is associated with plasma concentrations around 14 to 20 mg/L, while levels above 20 mg/L increase toxicity without clear added efficacy. A home-based volumetric absorptive microsampling approach showed poor correlation with venous plasma and appears unsuitable for routine use without a method-specific target range.11
  • PMID 31169262: In patients with ACC receiving mitotane, circulating total and acylated ghrelin levels increased during treatment, and higher mitotane concentrations correlated with acylated ghrelin measures. Higher ghrelin levels were associated with greater risk of mitotane-related side effects, suggesting a potential biomarker of treatment tolerability.111
  • PMID 31639772: In retrospective multicenter experience, temozolomide used as second- to fourth-line therapy for advanced ACC after progression on mitotane-based treatment achieved disease control in 35.8% of patients, but median progression-free and overall survival remained short at 3.5 and 7.2 months. Responses appeared more frequent in tumors with MGMT promoter methylation and toxicity was mostly grade 1-2.112
  • PMID 31683663: This pharmacokinetic modeling study of mitotane in ACC found marked interpatient variability in clearance, influenced by HDL, triglycerides, and a putative ultrafast-metabolizer subgroup. Simulations suggested standard starting regimens often fail to achieve the therapeutic plasma threshold by 3 months, supporting individualized dosing and therapeutic drug monitoring.39
  • PMID 31826297: Mitotane requires therapeutic drug monitoring because of its narrow plasma therapeutic window of 14–20 μg/mL. This study describes a simplified, validated GC-EI-MS plasma assay with internal standardization, 0.25–40 μg/mL calibration range, and sample stability below 4°C, supporting routine mitotane level monitoring in clinical practice.113
  • PMID 31956212: This case report describes unresectable ENSAT stage IV ACC with lung metastases achieving delayed partial response and prolonged survival of about 53 months on mitotane monotherapy alone. It also highlights early apparent progression, later tumor shrinkage, and the need for dose adjustment and glucocorticoid replacement during treatment.114
  • PMID 32245135: In advanced adrenocortical carcinoma treated with mitotane with or without chemotherapy, longer time in the therapeutic plasma range of at least 14 mg/L was associated with clinical benefit and independently predicted overall survival. The study supports routine mitotane level monitoring and reinforces a therapeutic window concept in metastatic care.45
  • PMID 32290298: In advanced or metastatic ACC, EDP-mitotane produced a 50% partial response rate with median progression-free survival of 10.1 months and overall survival of 18.7 months in a single-center series. The report also notes that apparent early progression without new lesions may not indicate treatment failure when mitotane levels remain subtherapeutic.55
  • PMID 32607875: This pharmacokinetic study of mitotane in adults with ACC developed a two-compartment population model showing that lean body weight, fat amount, and selected CYP2C19, SLCO1B1, and SLCO1B3 variants influence drug disposition. Model-based individualized starting doses may shorten time to the therapeutic plasma range of 14–20 mg/L while reducing toxicity risk, pending further validation.40
  • PMID 33019484: This case report highlights that mitotane can cause severe neurologic toxicity even during early low-dose treatment, with symptoms emerging after 4 months when plasma concentration reached 42.8 mg/L. It supports therapeutic drug monitoring to maintain the usual 14 to 20 mg/L target range and to prompt dose interruption when neurotoxicity or toxic levels occur.61
  • PMID 33279475: This review summarizes medical treatment standards for aggressive or advanced ACC, highlighting mitotane as the core adrenolytic therapy with serum-level monitoring and glucocorticoid replacement, and EDP-mitotane as the first-line chemotherapy backbone. It also notes limited activity of second-line cytotoxic options and temozolomide after prior treatment failure.24
  • PMID 33382119: This review summarizes mitotane as the only FDA-approved adrenolytic drug for ACC, outlining its role as monotherapy after surgery or for less progressive disease and in combination regimens for advanced disease. It emphasizes slow attainment of therapeutic plasma levels, major pharmacokinetic variability, and dose-limiting gastrointestinal and neurologic toxicity.115
  • PMID 33807024: In a retrospective adjuvant ACC cohort treated with mitotane after complete resection, female sex was associated with lower plasma mitotane and o,p′-DDE concentrations and less frequent attainment of the 14–20 mg/L therapeutic range. The study suggests sex-specific modulation of mitotane dosing or monitoring, although recurrence-free and overall survival did not differ by sex.41
  • PMID 33886381: This review summarizes why mitotane dosing in ACC is difficult, emphasizing its narrow therapeutic window, marked interpatient pharmacokinetic variability, and toxicity burden. It highlights therapeutic drug monitoring, current high- versus low-dose initiation strategies, and emerging pharmacokinetic and pharmacogenetic models intended to personalize mitotane exposure.13
  • PMID 34176818: A small Japanese single-institution retrospective series found very limited efficacy of mitotane-based treatment in advanced ACC, with median overall survival of 7.2 months in systemic cases, no radiologic tumor shrinkage, and frequent discontinuation from progression or toxicity. The report also describes real-world low starting doses, dose modification, and adverse events including hallucination, mycobacteriosis, and liver injury.116
  • PMID 34208714: This study proposes a mechanistic explanation for mitotane’s estrogen-like adverse effects in ACC, showing that mitotane can directly bind and activate estrogen receptor-α in preclinical models. The findings may help explain gynecomastia, menstrual abnormalities, and related endocrine effects observed during long-term mitotane treatment.59
  • PMID 34287806: This review highlights mitotane as the long-standing backbone of adjuvant and palliative ACC therapy while emphasizing major pharmacokinetic limitations of the current oral tablet formulation, including poor solubility, variable absorption, delayed attainment of therapeutic plasma levels, prolonged half-life, and associated adverse effects.8
  • PMID 35014973: In a retrospective ACC cohort receiving mitotane, concomitant spironolactone use was associated with lower mitotane plasma concentrations, lower concentration-to-dose ratios, and markedly reduced time within the therapeutic range despite higher mitotane doses. These findings suggest a clinically relevant drug interaction that may require dose adjustment or alternative supportive therapy.117
  • PMID 35272132: A single-center phase II trial found cabazitaxel to be well tolerated but poorly active as second- or third-line therapy in metastatic ACC after progression on cisplatin-containing treatment plus mitotane, with no RECIST responses, 24% disease control at 4 months, median progression-free survival of 1.5 months, and median overall survival of 6 months.118
  • PMID 35847963: In Chinese patients with advanced ACC treated with mitotane, plasma trough concentrations were positively associated with cumulative dose, while CYP2B6 516GG and 26570CC genotypes were independently associated with underexposure below the therapeutic threshold. The study supports therapeutic drug monitoring and suggests pharmacogenetic variability may partly explain difficulty achieving target mitotane levels.42
  • PMID 35876101: This review summarizes current ACC pharmacotherapy, identifying adjuvant mitotane for high-risk resected disease and mitotane alone or combined with EDP chemotherapy as the standard systemic approach for advanced or metastatic ACC. It also notes mitotane target plasma levels, toxicity threshold, and the lack of established options after progression on EDP-mitotane.5
  • PMID 36379398: This pharmaceutical study examines mitotane, the only approved non-surgical drug for adrenocortical carcinoma, emphasizing its poor aqueous solubility, low and variable oral absorption, bioavailability under 40%, and delayed attainment of therapeutic serum levels. It also reports that bulk amorphous mitotane is unstable to recrystallization near room temperature, limiting the translational promise of amorphous formulations outside nanoconfined micellar systems.37
  • PMID 37435450: In ACC patients treated with mitotane, clinically significant elevations in LDL cholesterol, triglycerides, HDL cholesterol, and non-HDL cholesterol occur during the first treatment year, with LDL and non-HDL peaks usually reached within 6 months. The study supports routine lipid monitoring during mitotane therapy and notes associations between mitotane concentration and several lipid parameters.19
  • PMID 37645432: A pilot study in five ACC patients receiving mitotane found neurophysiological and neuropsychological abnormalities associated with plasma levels above 18 mg/L, with partial or delayed improvement after level normalization. The findings reinforce the need for therapeutic drug monitoring and dose adjustment because neurological toxicity may persist despite clinical improvement.62
  • PMID 37977106: A Dutch population-based study of metastatic ACC found that introduction of EDP-mitotane in routine practice was associated with numerically longer median overall survival but no statistically significant survival advantage. Survival improved over time, while selected patients receiving mitotane and multimodality care also showed favorable outcomes.119
  • PMID 38056082: This case report highlights a practical pitfall in mitotane therapeutic drug monitoring for ACC: severe hypertriglyceridemia can cause spuriously high measured mitotane levels without corresponding toxicity. The report supports fasting sampling at least 12 hours after the last dose and evaluation and treatment of dyslipidemia when levels are unexpectedly high or fluctuate.52
  • PMID 39128398: This study validates a simple LC-DAD plasma assay for mitotane therapeutic drug monitoring in ACC, supporting dose adjustment during treatment. The method showed good linearity, precision, and agreement with GC-MS, and aligns with the need to maintain mitotane in the therapeutic range while limiting toxicity.120
  • PMID 39172357: In prospective metastatic ACC data, higher and earlier total plasma mitotane exposure was associated with longer overall survival, while free mitotane and lipoprotein-bound fractions did not add prognostic value beyond total levels. The findings support early total-level monitoring and suggest an effective threshold around 10-15 mg/L or cumulative exposure above 100 mg/L/month.16
  • PMID 39339230: This preclinical pharmaceutics study addresses a major limitation of mitotane therapy in ACC by developing a powder self-emulsifying oral formulation that improved dissolution and rat bioavailability compared with conventional Lysodren. The article highlights mitotane’s poor solubility, delayed achievement of therapeutic plasma levels, and toxicity burden with current high-dose oral treatment.66
  • PMID 39571650: This pharmacovigilance analysis of FAERS reports for mitotane in ACC confirmed expected toxicities such as nausea, diarrhea, vomiting, dizziness, appetite loss, and adrenal insufficiency, and identified additional potential signals including fatigue, amnesia, ovarian cysts, and QT-interval prolongation. The study emphasizes close adverse-event monitoring, especially during the first months of treatment.20
  • PMID 39682247: This review positions mitotane as the therapeutic backbone of ACC, summarizing its pharmacokinetics, therapeutic drug range, adrenal-specific steroidogenesis disruption, toxicity constraints, and use across adjuvant, monotherapy, and EDP-mitotane-based advanced disease settings.3
  • PMID 40746504: This case report describes a patient with rapidly growing metastatic unresectable ACC who achieved marked radiographic regression on mitotane monotherapy after chemotherapy was stopped for acute kidney injury. It highlights that meaningful responses can occur despite subtherapeutic plasma mitotane levels, while validated predictors of monotherapy benefit remain lacking.48
  • PMID 41399485: This pharmacology study suggests that mitotane distribution and apparent plasma concentrations are strongly influenced by lipoproteins, particularly VLDL-related lipid fractions. It reports that transient postprandial chylomicemia can cause pseudoelevated levels, supports freezing and centrifugation pretreatment for therapeutic drug monitoring, and proposes lipid-informed mitotane dosing hypotheses requiring clinical validation.22
  • PMID 11004720: A 2000 review argued that mitotane’s activity depends on metabolic transformation in adrenal tissue and suggested that tumor-specific metabolic capacity might help explain heterogeneous response. It also described early experimental work on response-prediction assays and more potent brominated mitotane analogs, framing these as investigational directions rather than established practice.34
  • PMID 1320600: A veterinary comparative study found that dogs with adrenal tumors, including adrenocortical carcinomas, were less biochemically responsive to mitotane and required higher doses than dogs with pituitary-dependent hyperadrenocorticism. This provides indirect historical support for variable tumor-specific sensitivity to mitotane, though its relevance to human ACC is limited.121
  • PMID 31544707: A 2020 case report described prolonged adrenal insufficiency after mitotane discontinuation, underscoring that endocrine consequences can outlast active treatment by a considerable interval. This supports the note’s emphasis on slow washout and the need for continued post-treatment monitoring.58
  • PMID 31265639: An erratum references a case report of rapid, complete, and durable remission of metastatic ACC with mitotane monotherapy, reinforcing that exceptional responses can occur even though they remain uncommon and anecdotal.122

References

Footnotes

  1. Mitotane treatment for adrenocortical carcinoma: an overview.. Minerva Endocrinol. 2012. PMID: 22382612. Local full text: 22382612.md ↩ ↩2 ↩3

  2. Role of Mitotane in Adrenocortical Carcinoma - Review and State of the art.. Eur Endocrinol. 2018. PMID: 30349596. Local full text: 30349596.md ↩ ↩2 ↩3 ↩4

  3. A Review on Mitotane: A Target Therapy in Adrenocortical Carcinoma.. Cancers (Basel). 2024. PMID: 39682247. Local full text: 39682247.md ↩ ↩2 ↩3 ↩4 ↩5 ↩6

  4. [Adrenocortical carcinomas: therapeutic advances in 2011].. Ann Endocrinol (Paris). 2011. PMID: 22008276. Local full text: 22008276.md ↩ ↩2 ↩3 ↩4

  5. Advances in adrenocortical carcinoma pharmacotherapy: what is the current state of the art?. Expert Opin Pharmacother. 2022. PMID: 35876101. Local full text: 35876101.md ↩ ↩2 ↩3 ↩4

  6. Blood levels of o,p’-DDD following administration in various vehicles after a single dose and during long-term treatment.. Cancer Chemother Pharmacol. 1981. PMID: 7340988. Local full text: 7340988.md ↩ ↩2

  7. Development of a pharmacokinetic model of mitotane: toward personalized dosing in adrenocortical carcinoma.. Ther Drug Monit. 2015. PMID: 24887633. Local full text: 24887633.md ↩ ↩2 ↩3 ↩4

  8. The Challenging Pharmacokinetics of Mitotane: An Old Drug in Need of New Packaging.. Eur J Drug Metab Pharmacokinet. 2021. PMID: 34287806. Local full text: 34287806.md ↩ ↩2 ↩3

  9. Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p’DDD) levels on the treatment of patients with adrenocortical carcinoma.. Cancer. 2001. PMID: 11745214. Local full text: 11745214.md ↩ ↩2 ↩3 ↩4 ↩5

  10. Therapeutic drug monitoring of mitotane: Analytical assay and patient follow-up.. Biomed Chromatogr. 2017. PMID: 28432798. Local full text: 28432798.md ↩ ↩2 ↩3 ↩4

  11. A method for the minimally invasive drug monitoring of mitotane by means of volumetric absorptive microsampling for a home-based therapeutic drug monitoring.. Anal Bioanal Chem. 2019. PMID: 31093700. Local full text: 31093700.md ↩ ↩2

  12. Current and emerging therapies for advanced adrenocortical carcinoma.. Oncologist. 2011. PMID: 21212436. Local full text: 21212436.md ↩ ↩2

  13. How close are we to personalized mitotane dosing in the treatment of adrenocortical carcinoma? State of the art and future perspectives.. Expert Opin Drug Metab Toxicol. 2021. PMID: 33886381. Local full text: 33886381.md ↩ ↩2 ↩3 ↩4

  14. Plasma concentrations of o,p’DDD, o,p’DDA, and o,p’DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study.. J Clin Endocrinol Metab. 2011. PMID: 21470991. Local full text: 21470991.md ↩ ↩2 ↩3

  15. Efficacy and safety of mitotane in the treatment of adrenocortical carcinoma: A retrospective study in 34 Belgian patients.. Ann Endocrinol (Paris). 2016. PMID: 27063476. Local full text: 27063476.md ↩ ↩2 ↩3

  16. Prognostic value of total, free and lipoprotein fraction-bound plasma mitotane levels in advanced adrenocortical carcinoma: a prospective study of the ENDOCAN-COMETE-Cancer network.. J Endocrinol Invest. 2025. PMID: 39172357. Local full text: 39172357.md ↩ ↩2 ↩3 ↩4

  17. Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma.. Clin Endocrinol (Oxf). 2011. PMID: 21883349. Local full text: 21883349.md ↩ ↩2 ↩3 ↩4

  18. Mitotane-induced hyperlipidemia: a retrospective cohort study.. Int J Endocrinol. 2013. PMID: 24348556. Local full text: 24348556.md ↩ ↩2 ↩3

  19. Characterization of hyperlipidemia secondary to mitotane in adrenocortical carcinoma.. Endocr Oncol. 2022. PMID: 37435450. Local full text: 37435450.md ↩ ↩2 ↩3

  20. Comprehensive Analysis of Mitotane-Related Adverse Events Using the Food and Drug Administration Adverse Event Reporting System.. Endocr Pract. 2025. PMID: 39571650. Local full text: 39571650.md ↩ ↩2 ↩3

  21. Dyslipidemia causes overestimation of plasma mitotane measurements.. Endocrinol Diabetes Metab Case Rep. 2016. PMID: 27298727. Local full text: 27298727.md ↩ ↩2 ↩3

  22. VLDL: The key factors influencing the distribution of mitotane in patients with adrenocortical carcinoma.. J Pharm Anal. 2025. PMID: 41399485. Local full text: 41399485.md ↩ ↩2 ↩3

  23. Adrenocortical carcinoma: the management of metastatic disease.. Crit Rev Oncol Hematol. 2014. PMID: 24958272. Local full text: 24958272.md ↩ ↩2

  24. Medical management of adrenocortical carcinoma: Current recommendations, new therapeutic options and future perspectives.. Ann Endocrinol (Paris). 2021. PMID: 33279475. Local full text: 33279475.md ↩ ↩2 ↩3

  25. Complete Responses to Mitotane in Metastatic Adrenocortical Carcinoma-A New Look at an Old Drug.. Oncologist. 2017. PMID: 28559412. Local full text: 28559412.md ↩ ↩2 ↩3

  26. Mitotane Monotherapy in Patients With Advanced Adrenocortical Carcinoma.. J Clin Endocrinol Metab. 2018. PMID: 29452402. Local full text: 29452402.md ↩ ↩2 ↩3 ↩4

  27. New insights and future perspectives in the therapeutic strategy of adrenocortical carcinoma (Review).. Oncol Rep. 2017. PMID: 28184938. Local full text: 28184938.md ↩ ↩2

  28. Fine structural effects of a DDT derivative on a rat adrenocortical carcinoma.. Histochem J. 1984. PMID: 6715193. Local full text: 6715193.md ↩ ↩2

  29. Mitotane alters mitochondrial respiratory chain activity by inducing cytochrome c oxidase defect in human adrenocortical cells.. Endocr Relat Cancer. 2013. PMID: 23696597. Local full text: 23696597.md ↩ ↩2

  30. The adrenal specific toxicant mitotane directly interacts with lipid membranes and alters membrane properties depending on lipid composition.. Mol Cell Endocrinol. 2016. PMID: 27002491. Local full text: 27002491.md ↩ ↩2

  31. Understanding mitotane mode of action.. J Physiol Pharmacol. 2017. PMID: 28456766. Local full text: 28456766.md ↩ ↩2

  32. Metabolic activation and binding of mitotane in adrenal cortex homogenates.. J Pharm Sci. 1995. PMID: 7738789. Local full text: 7738789.md ↩ ↩2

  33. Bovine adrenal cortex transformations of mitotane [1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane; o,p’-DDD] and its p,p’- and m,p’-isomers.. Biochem Pharmacol. 1995. PMID: 7763292. Local full text: 7763292.md ↩ ↩2

  34. Conventional and novel strategies in the treatment of adrenocortical cancer.. Braz J Med Biol Res. 2000. PMID: 11004720. Local full text: 11004720.md ↩ ↩2

  35. The lack of antitumor effects of o,p’DDA excludes its role as an active metabolite of mitotane for adrenocortical carcinoma treatment.. Horm Cancer. 2014. PMID: 25026941. Local full text: 25026941.md ↩ ↩2

  36. Development of microemulsion of mitotane for improvement of oral bioavailability.. Drug Dev Ind Pharm. 2010. PMID: 19778161. Local full text: 19778161.md ↩ ↩2

  37. Glass transition, crystallization kinetics, and inter-conformer relaxation dynamics of amorphous mitotane and related compounds.. Int J Pharm. 2022. PMID: 36379398. Local full text: 36379398.md ↩ ↩2

  38. Enzyme autoinduction by mitotane supported by population pharmacokinetic modelling in a large cohort of adrenocortical carcinoma patients.. Eur J Endocrinol. 2018. PMID: 30087117. Local full text: 30087117.md ↩ ↩2

  39. Population Pharmacokinetics Modelling and Simulation of Mitotane in Patients with Adrenocortical Carcinoma: An Individualized Dose Regimen to Target All Patients at Three Months?. Pharmaceutics. 2019. PMID: 31683663. Local full text: 31683663.md ↩ ↩2

  40. Population Pharmacokinetic and Pharmacogenetic Analysis of Mitotane in Patients with Adrenocortical Carcinoma: Towards Individualized Dosing.. Clin Pharmacokinet. 2021. PMID: 32607875. Local full text: 32607875.md ↩ ↩2 ↩3

  41. Sex Differences on Mitotane Concentration and Treatment Outcome in Patients with Adrenocortical Carcinoma.. Life (Basel). 2021. PMID: 33807024. Local full text: 33807024.md ↩ ↩2

  42. The Effects of Cumulative Dose and Polymorphisms in CYP2B6 on the Mitotane Plasma Trough Concentrations in Chinese Patients With Advanced Adrenocortical Carcinoma.. Front Oncol. 2022. PMID: 35847963. Local full text: 35847963.md ↩ ↩2

  43. Low-dose monitored mitotane treatment achieves the therapeutic range with manageable side effects in patients with adrenocortical cancer.. J Clin Endocrinol Metab. 2000. PMID: 10852456. Local full text: 10852456.md ↩ ↩2

  44. The treatment of adrenocortical carcinoma with o,p’-DDD: prognostic implications of serum level monitoring.. Eur J Cancer Clin Oncol. 1984. PMID: 6537915. Local full text: 6537915.md ↩ ↩2

  45. Mitotane Concentrations Influence Outcome in Patients with Advanced Adrenocortical Carcinoma.. Cancers (Basel). 2020. PMID: 32245135. Local full text: 32245135.md ↩ ↩2

  46. Changes in neoplastic cell features and sensitivity to mitotane during mitotane-induced remission in a patient with recurrent, metastatic adrenocortical carcinoma.. Endocr Relat Cancer. 1999. PMID: 10730906. Local full text: 10730906.md ↩ ↩2

  47. Lipoprotein-Free Mitotane Exerts High Cytotoxic Activity in Adrenocortical Carcinoma.. J Clin Endocrinol Metab. 2015. PMID: 26120791. Local full text: 26120791.md ↩ ↩2

  48. Extraordinary Response to Mitotane Monotherapy in Advanced Aggressive Adrenocortical Carcinoma.. JCEM Case Rep. 2025. PMID: 40746504. Local full text: 40746504.md ↩ ↩2

  49. A high-pressure liquid chromatographic method for measuring mitotane [1,1-(o,p’-Dichlorodiphenyl)-2,2-dichloroethane] and its metabolite 1,1-(o,p’-Dichlorodiphenyl)-2,2-dichloroethene in plasma.. Ther Drug Monit. 1995. PMID: 8585118. Local full text: 8585118.md ↩ ↩2

  50. Mitotane has a strong and a durable inducing effect on CYP3A4 activity.. Eur J Endocrinol. 2011. PMID: 21220434. Local full text: 21220434.md ↩ ↩2 ↩3 ↩4

  51. Short-term variation in plasma mitotane levels confirms the importance of trough level monitoring.. Eur J Endocrinol. 2014. PMID: 25201518. Local full text: 25201518.md ↩ ↩2

  52. Hypertriglyceridemia and its impact on mitotane monitoring in adrenocortical carcinoma.. Endocrinol Diabetes Metab Case Rep. 2023. PMID: 38056082. Local full text: 38056082.md ↩ ↩2

  53. High-dose mitotane strategy in adrenocortical carcinoma: prospective analysis of plasma mitotane measurement during the first 3 months of follow-up.. Eur J Endocrinol. 2012. PMID: 22048971. Local full text: 22048971.md ↩ ↩2

  54. Early progression under mitotane and polychemotherapy does not mean failure in adrenocortical carcinoma patient.. Ann Endocrinol (Paris). 2017. PMID: 27887670. Local full text: 27887670.md ↩ ↩2

  55. Efficacy of the EDP-M Scheme Plus Adjunctive Surgery in the Management of Patients with Advanced Adrenocortical Carcinoma: The Brescia Experience.. Cancers (Basel). 2020. PMID: 32290298. Local full text: 32290298.md ↩ ↩2

  56. Time Until Partial Response in Metastatic Adrenocortical Carcinoma Long-Term Survivors.. Horm Cancer. 2018. PMID: 29071575. Local full text: 29071575.md ↩ ↩2

  57. Treatment of adrenocortical carcinoma with o,p’-DDD.. Med Clin North Am. 1972. PMID: 5034421. Local full text: 5034421.md ↩ ↩2

  58. Prolonged Adrenal Insufficiency After the Discontinuation of Mitotane Therapy.. Endocr Metab Immune Disord Drug Targets. 2020. PMID: 31544707. Local full text: 31544707.md ↩ ↩2

  59. Estrogen-Like Effect of Mitotane Explained by Its Agonist Activity on Estrogen Receptor-α.. Biomedicines. 2021. PMID: 34208714. Local full text: 34208714.md ↩ ↩2

  60. High-Dose Mitotane-Induced Encephalopathy in the Treatment of Adrenocortical Carcinoma.. Oncologist. 2018. PMID: 29192018. Local full text: 29192018.md ↩ ↩2

  61. A case report of neurological adverse events caused by short-term and low-dose treatment of mitotane: The role of therapeutic drug monitoring.. Medicine (Baltimore). 2020. PMID: 33019484. Local full text: 33019484.md ↩ ↩2

  62. Neurological adverse events of mitotane in adrenocortical carcinoma: results of a pilot study.. Front Oncol. 2023. PMID: 37645432. Local full text: 37645432.md ↩ ↩2 ↩3

  63. Mitotane induces CYP3A4 expression via activation of the steroid and xenobiotic receptor.. J Endocrinol. 2013. PMID: 23179081. Local full text: 23179081.md ↩ ↩2

  64. Effects of adrenolytic mitotane on drug elimination pathways assessed in vitro.. Endocrine. 2015. PMID: 25542188. Local full text: 25542188.md ↩ ↩2

  65. Pharmacokinetic interaction between mitotane and etoposide in adrenal carcinoma: a pilot study.. Endocr Connect. 2018. PMID: 30533000. Local full text: 30533000.md ↩ ↩2

  66. Powder Self-Emulsifying Drug Delivery System for Mitotane: In Vitro and In Vivo Evaluation.. Pharmaceutics. 2024. PMID: 39339230. Local full text: 39339230.md ↩ ↩2

  67. o,p’DDD therapy in invasive adrenocortical carcinoma.. Ann Intern Med. 1975. PMID: 1137262. Local full text: 1137262.md ↩

  68. Suramin in adrenal cancer: modulation of steroid hormone production, cytotoxicity in vitro, and clinical antitumor effect.. J Clin Endocrinol Metab. 1990. PMID: 2380344. Local full text: 2380344.md ↩

  69. Mitotane therapy of adrenocortical carcinoma.. N Engl J Med. 1990. PMID: 2388676. Local full text: 2388676.md ↩

  70. Treatment of hormone-producing adrenocortical cancer with o,p’DDD and streptozocin.. Cancer. 1987. PMID: 2949824. Local full text: 2949824.md ↩

  71. Treatment of adrenocortical carcinoma: a case report and review of the literature.. Drug Intell Clin Pharm. 1986. PMID: 3510844. Local full text: 3510844.md ↩

  72. [The effects of o,p’-DDD on adrenal steroidogenesis and hepatic steroid metabolism].. Nihon Naibunpi Gakkai Zasshi. 1985. PMID: 3874792. Local full text: 3874792.md ↩

  73. A case of adrenocortical cancer treated with O,P’-DDD.. Endocrinol Jpn. 1969. PMID: 5819718. Local full text: 5819718.md ↩

  74. Adrenocortical carcinoma responded to treatment with o,p’-DDD—a case report.. Endocrinol Jpn. 1984. PMID: 6097439. Local full text: 6097439.md ↩

  75. O,p’-DDD (mitotane) levels in plasma and tissues during chemotherapy and at autopsy.. Cancer Chemother Pharmacol. 1982. PMID: 7172409. Local full text: 7172409.md ↩

  76. Complete remission of metastasized adrenocortical carcinoma under o,p’-DDD.. Exp Clin Endocrinol. 1994. PMID: 8005209. Local full text: 8005209.md ↩

  77. Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients.. Br J Cancer. 1994. PMID: 8180029. Local full text: 8180029.md ↩

  78. Phase II trial of mitotane and cisplatin in patients with adrenal carcinoma: a Southwest Oncology Group study.. J Clin Oncol. 1993. PMID: 8418229. Local full text: 8418229.md ↩

  79. [Therapy of the adrenocortical carcinoma with Lysodren (o,p’-DDD). Therapeutic management by monitoring o,p’-DDD blood levels].. Med Klin (Munich). 2001. PMID: 11494911. Local full text: 11494911.md ↩

  80. Sustained remission of metastatic adrenal carcinoma during long-term administration of low-dose mitotane.. J Endocrinol Invest. 2001. PMID: 11508789. Local full text: 11508789.md ↩

  81. Cytochrome P450-catalyzed binding of 3-methylsulfonyl-DDE and o,p’-DDD in human adrenal zona fasciculata/reticularis.. J Clin Endocrinol Metab. 2002. PMID: 11889204. Local full text: 11889204.md ↩

  82. TREATMENT OF ADRENOCORTICAL CANCER WITH O,P’-DDD.. Ann Intern Med. 1963. PMID: 14042612. Local full text: 14042612.md ↩

  83. ADRENOCORTICAL CARCINOMA TREATED WITH O,P’ -DDD.. Br Med J. 1965. PMID: 14280300. Local full text: 14280300.md ↩

  84. Rapidly progressing high o,p’DDD doses shorten the time required to reach the therapeutic threshold with an acceptable tolerance: preliminary results.. Clin Endocrinol (Oxf). 2006. PMID: 16402938. Local full text: 16402938.md ↩

  85. Systemic chemotherapy for adrenocortical carcinoma: comparative responses to conventional first-line therapies.. Anticancer Drugs. 2008. PMID: 18525324. Local full text: 18525324.md ↩

  86. Emerging drugs for adrenocortical carcinoma.. Expert Opin Emerg Drugs. 2008. PMID: 18764725. Local full text: 18764725.md ↩

  87. Metastatic virilizing adrenocortical carcinoma: a rare case of cure with surgery and mitotane therapy.. Clin Med Res. 2009. PMID: 19574489. Local full text: 19574489.md ↩

  88. Chiral effects in adrenocorticolytic action of o,p’-DDD (mitotane) in human adrenal cells.. Xenobiotica. 2010. PMID: 20044879. Local full text: 20044879.md ↩

  89. Mitotane serum level analysis; good agreement between two different assays.. Clin Endocrinol (Oxf). 2010. PMID: 20105188. Local full text: 20105188.md ↩

  90. [Combined therapy of advanced adrenal cortical adenocarcinoma].. Zhonghua Yi Xue Za Zhi. 2010. PMID: 21029628. Local full text: 21029628.md ↩

  91. Current and future medical therapy, and the molecular features of adrenocortical cancer.. Recent Pat Anticancer Drug Discov. 2012. PMID: 21854357. Local full text: 21854357.md ↩

  92. Therapeutic management of advanced adrenocortical carcinoma: what do we know in 2011?. Horm Cancer. 2011. PMID: 22161625. Local full text: 22161625.md ↩

  93. Simultaneous analysis of mitotane and its main metabolites in human blood and urine samples by SPE-HPLC technique.. Biomed Chromatogr. 2012. PMID: 22259022. Local full text: 22259022.md ↩

  94. Current and emerging therapeutic options in adrenocortical cancer treatment.. J Oncol. 2012. PMID: 22934112. Local full text: 22934112.md ↩

  95. Development of mitotane lipid nanocarriers and enantiomers: two-in-one solution to efficiently treat adreno-cortical carcinoma.. Curr Med Chem. 2012. PMID: 22934807. Local full text: 22934807.md ↩

  96. No evidence for relevant QT interval prolongation in mitotane-treated patients with adrenocortical carcinoma.. J Endocrinol Invest. 2012. PMID: 23013780. Local full text: 23013780.md ↩

  97. Mitotane reduces human and mouse ACTH-secreting pituitary cell viability and function.. J Endocrinol. 2013. PMID: 23814013. Local full text: 23814013.md ↩

  98. Comparison of two mitotane starting dose regimens in patients with advanced adrenocortical carcinoma.. J Clin Endocrinol Metab. 2013. PMID: 24057287. Local full text: 24057287.md ↩

  99. Metastatic adrenocortical carcinoma with a prolonged response to mitotane.. Oncology (Williston Park). 2014. PMID: 25144285. Local full text: 25144285.md ↩

  100. Contribution of Therapeutic Monitoring in the Assessment of Toxic Adverse Effects of Mitotane: a Case Report.. Therapie. 2015. PMID: 26242497. Local full text: 26242497.md ↩

  101. Subacute Cutaneous Lupus Erythematosus Induced by Mitotane.. JAMA Dermatol. 2016. PMID: 26444320. Local full text: 26444320.md ↩

  102. Association of mitotane with chylomicrons and serum lipoproteins: practical implications for treatment of adrenocortical carcinoma.. Eur J Endocrinol. 2016. PMID: 26671975. Local full text: 26671975.md ↩

  103. Salvage Treatment of Adrenocortical Carcinoma with Trofosfamide.. Horm Cancer. 2016. PMID: 26961793. Local full text: 26961793.md ↩

  104. Rapid and Complete Remission of Metastatic Adrenocortical Carcinoma Persisting 10 Years After Treatment With Mitotane Monotherapy: Case Report and Review of the Literature.. Medicine (Baltimore). 2016. PMID: 27043680. Local full text: 27043680.md ↩

  105. Oral and vulvo-vaginal lichenoid reactions due to mitotane (Lysodren): A case report.. Medicine (Baltimore). 2017. PMID: 28079787. Local full text: 28079787.md ↩

  106. Circannual variation of mitotane and its metabolites plasma levels in patients with adrenocortical carcinoma.. J Pharm Pharmacol. 2017. PMID: 28809444. Local full text: 28809444.md ↩

  107. Clinical Case of Metastatic Adrenocortical Carcinoma With Unusual Evolution: Review the Literature.. World J Oncol. 2015. PMID: 28983351. Local full text: 28983351.md ↩

  108. Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor use in the management of resistant hypercholesterolemia induced by mitotane treatment for adrenocortical cancer.. J Clin Lipidol. 2018. PMID: 29650402. Local full text: 29650402.md ↩

  109. Mitotane-induced dyspnoea: an unusual side effect.. BMJ Case Rep. 2018. PMID: 30173131. Local full text: 30173131.md ↩

  110. A case report of a TDM-guided optimization of mitotane for a safe and effective long-term treatment.. J Chemother. 2019. PMID: 30831058. Local full text: 30831058.md ↩

  111. Changes in total and acylated ghrelin levels during mitotane treatment in patients with adrenocortical carcinoma.. Pol Arch Intern Med. 2019. PMID: 31169262. Local full text: 31169262.md ↩

  112. Activity and safety of temozolomide in advanced adrenocortical carcinoma patients.. Eur J Endocrinol. 2019. PMID: 31639772. Local full text: 31639772.md ↩

  113. A simplified method for therapeutic drug monitoring of mitotane by gas chromatography-electron ionization-mass spectrometry.. Biomed Chromatogr. 2020. PMID: 31826297. Local full text: 31826297.md ↩

  114. [A CASE REPORT: A PATIENT WITH METASTATIC ADRENOCORTICAL CARCINOMA EXCLUSIVELY TREATED WITH MITOTANE WITH LONG-TERM FOLLOW-UP].. Nihon Hinyokika Gakkai Zasshi. 2019. PMID: 31956212. Local full text: 31956212.md ↩

  115. Pharmacological profile and effects of mitotane in adrenocortical carcinoma.. Br J Clin Pharmacol. 2021. PMID: 33382119. Local full text: 33382119.md ↩

  116. Japanese single-institution analysis of mitotane for patients with adrenocortical carcinoma.. Endocr J. 2021. PMID: 34176818. Local full text: 34176818.md ↩

  117. Spironolactone is associated with reduced mitotane levels in adrenocortical carcinoma patients.. Endocr Relat Cancer. 2022. PMID: 35014973. Local full text: 35014973.md ↩

  118. Phase II study of cabazitaxel as second-third line treatment in patients with metastatic adrenocortical carcinoma.. ESMO Open. 2022. PMID: 35272132. Local full text: 35272132.md ↩

  119. Impact of EDP-M on survival of patients with metastatic adrenocortical carcinoma: A population-based study.. Eur J Cancer. 2024. PMID: 37977106. Local full text: 37977106.md ↩

  120. Development and validation of a liquid chromatography coupled to a diode array detector (LC-DAD) method for measuring mitotane (DDD) in plasma samples.. Clinics (Sao Paulo). 2024. PMID: 39128398. Local full text: 39128398.md ↩

  121. Comparison of mitotane treatment for adrenal tumor versus pituitary-dependent hyperadrenocorticism in dogs.. J Am Vet Med Assoc. 1992. PMID: 1320600. Local full text: 1320600.md ↩

  122. Erratum: Rapid and Complete Remission of Metastatic Adrenocortical Carcinoma Persisting 10 Years After Treatment With Mitotane Monotherapy: Case Report and Review of the Literature: Erratum.. Medicine (Baltimore). 2016. PMID: 31265639. Local full text: 31265639.md ↩

Graph View